GlassScriptPhysician profile
David H Zebrack
NPI 1891873329
$10,175.47
in general payments reported to CMS, 2019-2025
62 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,523 · 2020: $1,199 · 2021: $1,856 · 2022: $1,595 · 2023: $1,282 · 2024: $1,291 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,581.92 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,325.01 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $756.83 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $523.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $507.74 | 2019-2025 | Spravato |
| Lilly USA, LLC | $469.56 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $399.40 | 2019-2023 | Lifevest |
| Glaxosmithkline, LLC. | $345.64 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.72 | 2023-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $309.63 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Allergan, INC. | $295.33 | 2019-2020 | |
| Pfizer INC. | $286.21 | 2019-2025 | |
| Abbott Laboratories | $281.57 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Amarin Pharma, INC. | $279.00 | 2019-2022 | |
| Exact Sciences Corporation | $139.01 | 2023-2025 | Cologuard Collection Kit |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zebrack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.